Clinical Trials /

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

NCT02619669

Description:

Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation. The mTOR complex (mTORC) is an important therapeutic target that is generally stable (i.e., low tendency to mutate) and is a key intracellular point of convergence for a number of cellular signaling pathways. Inhibiting mTOR may inhibit abnormal cell proliferation, tumor angiogenesis, and abnormal cellular metabolism, thus providing the rationale for mTOR inhibitors as potential agents in the treatment of a number of indications including solid tumor and hematological malignancies, as either monotherapy or in combination with other chemotherapeutic agents. Like rapamycin, several newly approved rapalogs (temsirolimus and everolimus) are specific and allosteric inhibitors of mTORC1, and only partially inhibit mTORC1 signaling pathways. They do not directly inhibit mTORC2, which has shown to be an emerging target in cancer research. TAK-228 was developed to address the incomplete inhibition of the mTOR pathway by rapalogs. Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11. The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects.

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/<span class="go-doc-concept go-doc-biomarker">HER2</span>- Breast Cancer

Title

  • Brief Title: Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer
  • Official Title: Phase 1b Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer
  • Clinical Trial IDs

    NCT ID: NCT02619669

    ORG ID: D14012

    Trial Conditions

    Breast Cancer

    Trial Interventions

    Drug Synonyms Arms
    TAK-228 (MLN0128) TAK-228 (MLN0128) followed by TAK-228 (MLN0128) plus Letrozole
    Letrozole Femara TAK-228 (MLN0128) followed by TAK-228 (MLN0128) plus Letrozole

    Trial Purpose

    Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable
    adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase
    referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets
    2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently
    inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular
    proliferation.

    The mTOR complex (mTORC) is an important therapeutic target that is generally stable (i.e.,
    low tendency to mutate) and is a key intracellular point of convergence for a number of
    cellular signaling pathways. Inhibiting mTOR may inhibit abnormal cell proliferation, tumor
    angiogenesis, and abnormal cellular metabolism, thus providing the rationale for mTOR
    inhibitors as potential agents in the treatment of a number of indications including solid
    tumor and hematological malignancies, as either monotherapy or in combination with other
    chemotherapeutic agents. Like rapamycin, several newly approved rapalogs (temsirolimus and
    everolimus) are specific and allosteric inhibitors of mTORC1, and only partially inhibit
    mTORC1 signaling pathways. They do not directly inhibit mTORC2, which has shown to be an
    emerging target in cancer research. TAK-228 was developed to address the incomplete
    inhibition of the mTOR pathway by rapalogs.

    Eligible subjects will have a research biopsy and baseline blood and urine studies done
    within two weeks prior to start of study treatment. Subjects will then be treated with
    TAK-228 (MLN0128) for 10 days, and a repeat biopsy and pharmacokinetics will be done on day
    11. The subject will then be treated with the combination of TAK-228 (MLN0128) and letrozole
    for an additional 110 days, before undergoing resection of the primary tumor. Subjects will
    be treated at the recommended Phase II dose of TAK-228 (MLN0128) of 4 mg once daily, and a
    dose de-escalation to 3 mg daily will be performed if dose-limiting toxicity is seen in 1/3
    or more of the subjects at the first dose level. The maximum tolerated dose cohort will be
    expanded to include six to ten subjects.

    Detailed Description

    Trial Arms

    Name Type Description Interventions
    TAK-228 (MLN0128) followed by TAK-228 (MLN0128) plus Letrozole Experimental Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 (MLN0128) for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11. The subject will then be treated with the combination of TAK-228 (MLN0128) and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 (MLN0128) of 4 mg once daily, and a dose de-escalation to 3 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects. TAK-228 (MLN0128), Letrozole

    Eligibility Criteria

    Inclusion Criteria:

    1. Post-menopausal women 18 years of age with clinical stage I-IV, ER positive / HER2
    negative, breast cancer that will be managed by surgical resection. Patients with
    metastatic disease at diagnosis are eligible if clinically appropriate.

    The patient must have had a baseline MRI performed as standard-of-care that can be
    used to calculate the distance(s) of the longest dimension(s) of the primary
    tumor(s).

    2. Histologic documentation of breast cancer by core needle or incisional biopsy.

    3. Tumor size must be 2 cm in the longest dimension.

    4. Patients must be at high risk for recurrence, which will be defined during the
    pre-treatment screening period as meeting one of the following criteria:

    - A histologically positive nodal deposit 0.2 mm

    - Histologic Grade 3

    - Peritumoral lymphatic vessel or vascular invasion

    - Oncotype Dx score of 25 or greater

    5. The invasive cancer must be HER2-low, defined as IHC 0-1+, or with a FISH ratio of
    <1.8 if IHC is 2+ or if IHC has not been performed.

    6. The invasive cancer must be estrogen receptor alpha (ER)-positive, defined as having
    ER staining by IHC in 10% of malignant tumor cells.

    7. The subject must agree to 4 months (120 days) of neoadjuvant treatment with TAK-228
    and Letrozole, have blood draws and urine samples obtained, have research tumor
    biopsies performed at baseline and after 10 days of TAK-228 treatment, and have a
    repeat MRI performed prior to surgery (MRI is part of routine clinical care).

    8. ECOG performance status 0-1.

    9. Life expectancy of 12 months or longer.

    10. Adequate hematologic, hepatic, renal, and glycemic function:

    - Adequate bone marrow reserve: absolute neutrophil count (ANC) 1.5 x 109/L;
    platelet count 100 x 109/L; hemoglobin 9 g/dL;

    - Hepatic: total bilirubin 1.5 x upper limit of normal (ULN), transaminases
    (aspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and
    alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT) 2.5 x
    ULN;

    - Renal: creatinine clearance 50 mL/min based either on Cockcroft-Gault estimate
    or based on urine collection (12 or 24 hour);

    - Metabolic: fasting serum glucose ( 130 mg/dL) and fasting triglycerides 300
    mg/dL;

    11. Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of
    institutional standard of normal as measured by echocardiogram (ECHO) or multiple
    gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
    (i.e., if the institutional normal is 50%, subject's LVEF may be as low as 45% to be
    eligible for the study)

    12. Ability to swallow oral medications and maintain an empty stomach state for two hours
    prior to the TAK-228 dose and for one hour following administration.

    13. Ability to give informed consent.

    Exclusion Criteria:

    1. Any serious medical or psychiatric illness that could, in the investigator's opinion,
    potentially interfere with the completion of treatment according to this protocol.

    2. Any other presurgical therapy for breast cancer.

    3. Prior anti-estrogen therapy within the last 5 years.

    4. Prior treatment with an mTOR, AKT, or PI3K inhibitor.

    5. Treatment within the past two years with a bisphosphonate or a Rank ligand inhibitor.

    6. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI
    disease, or for an unknown reason that may alter the absorption of TAK-228. In
    addition, subjects with enteric stomata are also excluded.

    7. Poorly controlled diabetes mellitus defined as HbA1c > 7%. Subjects with a history of
    transient glucose intolerance due to corticosteroid administration are allowed in
    this study if all other inclusion/exclusion criteria are met.

    8. History of any of the following within the last 6 months prior to study entry:

    - Ischemic myocardial event, including angina requiring therapy and artery
    revascularization procedures.

    - Ischemic cerebrovascular event, including TIA and artery revascularization
    procedures.

    - Requirement for inotropic support (excluding digoxin) or serious (uncontrolled)
    cardiac arrhythmia (including atrial flutter/fibrillation, ventricular
    fibrillation or ventricular tachycardia).

    - Placement of a pacemaker for control of rhythm.

    - New York Heart Association (NYHA) Class III or IV heart failure (See Appendix
    B).

    - Pulmonary embolism.

    9. Significant active cardiovascular or pulmonary disease at the time of study entry,
    including:

    - Uncontrolled high blood pressure (i.e., systolic blood pressure >180 mm Hg,
    diastolic blood pressure > 95 mm Hg)

    - Pulmonary hypertension

    - Uncontrolled asthma or O2 saturation < 90% by ABG (Arterial Blood Gas) analysis
    or pulse oximetry on room air

    - Significant valvular disease; severe regurgitation or stenosis by imaging
    independent of symptom control with medical intervention, or history of valve
    replacement

    - Medically significant (symptomatic) bradycardia

    - History of arrhythmia requiring an implantable cardiac defibrillator

    - Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated
    demonstration of QTc interval > 480 milliseconds, or history of congenital long
    QT syndrome, or torsade de pointes)

    10. Treatment with strong CYP3A4 and CYP2C19 inhibitors and/or inducers must be
    discontinued at least 1 week before administration of the first dose of study
    drug.(see Appendix C)

    11. Initiation of treatment with hematopoietic growth factors, transfusions of blood and
    blood products, or systemic corticosteroids (either IV or oral steroids, excluding
    inhalers) within 1 week before administration of the first dose of study drug
    (patients already receiving erythropoietin on a chronic basis for 4 weeks are
    eligible).

    12. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease,
    active central nervous system disease, active infection, or any other condition that
    could compromise participation of the patient in the study.

    13. Central nervous system (CNS) metastasis.

    14. Known human immunodeficiency virus infection.

    15. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C
    infection.

    16. Patients receiving systemic corticosteroids (either IV or oral steroids, excluding
    inhalers or low-dose hormone replacement therapy) within 1 week before administration
    of the first dose of study drug.

    17. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI
    within 7 days before receiving the first dose of study drug.

    Minimum Eligible Age: 18 Years

    Maximum Eligible Age: N/A

    Eligible Gender: Female

    Primary Outcome Measures

    Evaluation of Treatment-Related Adverse Events as Assessed by NCI CTCAE v4.0

    Secondary Outcome Measures

    Pathologic Response Assessed by Analysis of Tissue Samples and RECIST Criteria

    Trial Keywords

    Neoadjuvant

    TAK-228 (MLN0128)

    Letrozole

    ER+

    HER2-